Quest Diagnostics (NYSE: DGX), Indianapolis, IN – FDA Inspections

Inspection records and compliance data for Quest Diagnostics in Indianapolis, Indiana. 7 FDA inspections on record, last inspected July 30, 2024. Publicly traded as NYSE: DGX.

Company Profile

This profile covers Quest Diagnostics based in Indianapolis, Indiana, United States.

FDA Inspection History

FDA inspections: 7
OAI: 0
VAI: 5
NAI: 2
Form 483s: 0
Warning letters: 0

First inspected September 30, 2009. Last inspected July 30, 2024.

Most cited issue areas

Establish, maintain and follow manufacturing SOPs4 inspections
Biological product deviation report1 inspection
Concurrent documentation1 inspection

FDA inspections (7)

Date	Result	FDA center(s)	Insp. #
July 30, 2024	NAI	Biologics · Blood and Blood Products	1245312
September 13, 2018	NAI	Biologics · Blood and Blood Products	1069321
August 25, 2016	VAI	Biologics · Blood and Blood Products	983437
July 28, 2014	VAI	Biologics · Blood and Blood Products	889102
September 18, 2012	VAI	Biologics · Blood and Blood Products	799707
September 22, 2010	VAI	Biologics · Blood and Blood Products	681842
September 30, 2009	VAI	Biologics · Blood and Blood Products	615803

FDA documents

No Form 483s, Warning Letters or EIRs on record.

Related Companies (10)

Companies with similar regulatory profiles, compliance history, and operations.

Methodist Hospitals, Inc.

Parkview North Hospital

CSL Plasma Inc.

Saturn Biomedical, Inc

Midwest Fertility Center

American National Red Cross

Midwest Fertility Specialists

Franciscan Health Indianapolis

Versiti Indiana, Inc.

Women's Specialty Health Centers, Pc